제일약품

271980KOSPI

68.4 / 100

Reference Date: 2026-09-08

Financial Score28.0 / 40

News Sentiment19.4 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly up 3.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharm was established in 2017 through a spin-off from Jeil Pharma Holdings, focusing on the manufacturing and sales of finished pharmaceutical products. Its subsidiary, Oncol Therapeutics, specializes in new drug development. Key products include treatments for hypercholesterolemia, hyperlipidemia, and gastric cancer, with major revenue contributors being Lipito tablets and Lyrica capsules.

Number of Employees

1,011people

Average Salary

63.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.82Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.62Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

13.61Industry Average 8.005.5Point

1.7x industry avg (good)

Debt Ratio

6.81Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼53.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 7Neutral 2Negative 0Average Sentiment Score 77.8

Neutral
"법적 역량 강화"…제일파마홀딩스, 계열사 교육
제일파마홀딩스의 법무 교육 실시는 내부 효율성 향상에 기여할 것으로 보이나, 직접적인 주가 영향은 제한적.
Neutral
제일파마홀딩스, 전 계열사 팀장 대상 법무교육 실시
제일파마홀딩스가 계열사 팀장들을 대상으로 법무 교육을 실시하여 법적 리스크 대응 능력을 강화하고 있으나, 직접적인 주식 영향은 제한적이다.
Positive
[혁신형 제약기업 점검]? 온코닉, 자큐보 수익 후속신약 재투자 검증
제일약품 자회사 온코닉테라퓨틱스의 혁신 신약 자큐보가 상업화 성공 후 혁신형 제약기업 인증을 받으며 긍정적인 성과를 보여주고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 10,500Won52-week high 17,39052-week low 9,230

1-month return4.0Point

1m +3.65% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14